CDK13

Summary

CDK13 (cyclin dependent kinase 13, HGNC:1733) is a protein-coding gene on chromosome 7p14.1, encoding Cyclin-dependent kinase 13 (Q14004). Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. It is haploinsufficient (ClinGen: sufficient evidence).

The protein encoded by this gene is a member of the cyclin-dependent serine/threonine protein kinase family. Members of this family are well known for their essential roles as master switches in cell cycle control. The exact function of this protein has not yet been determined, but it may play a role in mRNA processing and may be involved in regulation of hematopoiesis. Alternatively spliced transcript variants have been described.

Source: NCBI Gene 8621 — RefSeq curated summary.

At a glance

• Gene–disease (curated): syndromic intellectual disability (Definitive, ClinGen) — +1 more curated relationship
• GWAS associations: 5
• Clinical variants (ClinVar): 1,196 total — 40 pathogenic, 37 likely-pathogenic
• Phenotypes (HPO): 67
• Druggable target: yes — 20 molecules with ChEMBL bioactivity
• Dosage sensitivity (ClinGen): haploinsufficiency sufficient evidence, triplosensitivity no evidence
• MANE Select transcript: NM_003718

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1733
Approved symbol	CDK13
Name	cyclin dependent kinase 13
Location	7p14.1
Locus type	gene with protein product
Status	Approved
Aliases	CHED, CDC2L, KIAA1791
Ensembl gene	ENSG00000065883
Ensembl biotype	protein_coding
OMIM	603309
Entrez	8621

Gene structure

Transcript identifiers

Ensembl transcripts: 24 — 12 protein_coding, 6 retained_intron, 6 protein_coding_CDS_not_defined

ENST00000181839, ENST00000340829, ENST00000465643, ENST00000478563, ENST00000484589, ENST00000642213, ENST00000642592, ENST00000642626, ENST00000642660, ENST00000643859, ENST00000643868, ENST00000643915, ENST00000644221, ENST00000644561, ENST00000645470, ENST00000645826, ENST00000646039, ENST00000646437, ENST00000647453, ENST00000647518, ENST00000700485, ENST00000700486, ENST00000700487, ENST00000966764

RefSeq mRNA: 2 — MANE Select: NM_003718 NM_003718, NM_031267

CCDS: CCDS5461, CCDS5462

Canonical transcript exons

ENST00000181839 — 14 exons

Exon	Start	End
ENSE00000521990	40078720	40078851
ENSE00000832466	40078005	40078121
ENSE00000832468	40092785	40093237
ENSE00001709712	39987599	39988258
ENSE00001886832	39950256	39951852
ENSE00001942437	40094130	40099580
ENSE00003494733	40045836	40046025
ENSE00003525244	39997494	39997664
ENSE00003581011	40062826	40062927
ENSE00003586066	40001861	40002031
ENSE00003592719	40063023	40063100
ENSE00003629850	40047821	40047877
ENSE00003674806	39999361	39999500
ENSE00003687550	40088126	40088331

Expression profiles

Bgee: expression breadth ubiquitous, 297 present calls, max score 99.82.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 23.1769 / max 371.8702, expressed in 1813 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
78276	7.6433	1635
78274	7.3987	1774
78275	4.2767	1693
78273	1.8750	934
78279	1.0764	569
78277	0.4641	185
78278	0.3132	130
78280	0.1295	41

Top tissues by expression

300 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
buccal mucosa cell	CL:0002336	99.82	gold quality
renal medulla	UBERON:0000362	99.69	gold quality
visceral pleura	UBERON:0002401	99.67	gold quality
pylorus	UBERON:0001166	99.55	gold quality
nipple	UBERON:0002030	99.51	gold quality
endothelial cell	CL:0000115	99.47	gold quality
cardia of stomach	UBERON:0001162	99.47	gold quality
ventral tegmental area	UBERON:0002691	99.46	gold quality
inferior vagus X ganglion	UBERON:0005363	99.43	gold quality
parietal pleura	UBERON:0002400	99.42	gold quality
lateral globus pallidus	UBERON:0002476	99.40	gold quality
superior surface of tongue	UBERON:0007371	99.39	gold quality
trigeminal ganglion	UBERON:0001675	99.38	gold quality
subthalamic nucleus	UBERON:0001906	99.37	gold quality
superior vestibular nucleus	UBERON:0007227	99.37	gold quality
tibia	UBERON:0000979	99.34	gold quality
substantia nigra pars reticulata	UBERON:0001966	99.30	gold quality
substantia nigra pars compacta	UBERON:0001965	99.26	gold quality
pericardium	UBERON:0002407	99.06	gold quality
urethra	UBERON:0000057	98.99	gold quality
penis	UBERON:0000989	98.91	gold quality
superficial temporal artery	UBERON:0001614	98.85	gold quality
tendon of biceps brachii	UBERON:0008188	98.85	gold quality
synovial joint	UBERON:0002217	98.83	gold quality
lateral nuclear group of thalamus	UBERON:0002736	98.80	gold quality
adult organism	UBERON:0007023	98.80	gold quality
saphenous vein	UBERON:0007318	98.79	gold quality
pharyngeal mucosa	UBERON:0000355	98.78	gold quality
pleura	UBERON:0000977	98.76	gold quality
caput epididymis	UBERON:0004358	98.60	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-GEOD-75140	no	614.20
E-MTAB-2983	no	279.94
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

185 targeting CDK13, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-188-3P	100.00	68.76	1240
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-4282	99.99	75.36	6408
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-150-5P	99.99	66.69	1976
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-548N	99.98	71.94	4170
HSA-MIR-607	99.97	73.62	5593
HSA-MIR-9-3P	99.96	70.88	2068
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-590-3P	99.96	74.34	6478
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-3910	99.95	71.13	2227
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-6835-3P	99.93	70.49	2904
HSA-MIR-22-3P	99.93	68.13	917
HSA-MIR-205-3P	99.92	69.92	3165

Functional genomics

ClinGen dosage: haploinsufficiency 3 (sufficient evidence), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 24)

• Data demonstrate that CDC2L5 is located in the nucleoplasm, where it directly interacts with the ASF/SF2-associated protein p32, a protein involved in splicing regulation. (PMID:16721827)
• CDK13 interacts with cyclin K, and is required for self-renewal in ES cells. (PMID:22547058)
• Coincidently amplified CDK13, GMNN, and CENPF genes can play a role as common cancer-driver genes in human cancers. (PMID:22912832)
• High CDK13 expression is associated with pancreatic cancer. (PMID:25216700)
• CDK12 and CDK13 losses in HCT116 cells preferentially affect expression of DNA damage response. (PMID:25561469)
• CDK13 gene is amplified in different types of cancer indicate that this kinase can contribute to cancer development in human. (PMID:26886422)
• Mutation in CHK13 gene is associated with congenital heart defects. (PMID:27479907)
• Detailed phenotypic and molecular characterisation of 9 individuals with pathogenic variants in CDK13 is provided. Two individuals had novel CDK13 variants (p.Asn842Asp, p.Lys734Glu), while the remaining seven unrelated individuals had a recurrent, previously published p.Asn842Ser variant. (PMID:28807008)
• heterozygous, likely dominant negative mutations affecting the protein kinase domain of the CDK13 gene result in a recognisable, syndromic form of intellectual disability, with or without congenital heart disease. (PMID:29021403)
• Heterozygous constitutional CDK13 mutations in 3 patients cause intellectual disability without cardiac defects. (PMID:29222009)
• We demonstrate the synthesis of two aberrant CDK13 transcripts in lymphoblastoid cells from an individual with a splice-site variant. Clinical characteristics of the individuals include mild to severe intellectual disability (ID), developmental delay, behavioural problems, (neonatal) hypotonia and a variety of facial dysmorphism. (PMID:29393965)
• CDK13 RNA over-editing sites mediated by ADAR1 may serve as novel cancer driver events in HCC progression. (PMID:29996118)
• CDK13 is important for proper expression of a number of genes, but it also probably plays yet-to-be-discovered roles in other processes. (PMID:30319007)
• Insight into the molecular mechanism of LINC00152/miR-215/CDK13 axis in hepatocellular carcinoma progression. (PMID:31297882)
• Expression of CDK13 Was Associated with Prognosis and Expression of HIF-1alpha and beclin1 in Breast Cancer Patients. (PMID:33292020)
• CDK13 upregulation-induced formation of the positive feedback loop among circCDK13, miR-212-5p/miR-449a and E2F5 contributes to prostate carcinogenesis. (PMID:33390186)
• Wolfram-like syndrome with bicuspid aortic valve due to a homozygous missense variant in CDK13. (PMID:33879837)
• HIV-1 Nef interacts with the cyclin K/CDK13 complex to antagonize SERINC5 for optimal viral infectivity. (PMID:34380030)
• An ADAR1-dependent RNA editing event in the cyclin-dependent kinase CDK13 promotes thyroid cancer hallmarks. (PMID:34496885)
• CDK13-related disorder: Report of a series of 18 previously unpublished individuals and description of an epigenetic signature. (PMID:35063350)
• CDK13-related disorder: a deep characterization of speech and language abilities and addition of 33 novel cases. (PMID:36599938)
• CDK12/13 promote splicing of proximal introns by enhancing the interaction between RNA polymerase II and the splicing factor SF3B1. (PMID:37026485)
• Oncogenic CDK13 mutations impede nuclear RNA surveillance. (PMID:37079685)
• CDK13 promotes lipid deposition and prostate cancer progression by stimulating NSUN5-mediated m5C modification of ACC1 mRNA. (PMID:37845385)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	cdk13	ENSDARG00000076791
mus_musculus	Cdk13	ENSMUSG00000041297
rattus_norvegicus	Cdk13	ENSRNOG00000013620
drosophila_melanogaster	Cdk12	FBGN0037093

Paralogs (26): CDKL3 (ENSG00000006837), CDKL5 (ENSG00000008086), CDK11A (ENSG00000008128), CDK14 (ENSG00000058091), CDK17 (ENSG00000059758), CDKL1 (ENSG00000100490), CDK16 (ENSG00000102225), CDK6 (ENSG00000105810), PRP4K (ENSG00000112739), CDK18 (ENSG00000117266), CDK2 (ENSG00000123374), CDK8 (ENSG00000132964), CDK7 (ENSG00000134058), CDK4 (ENSG00000135446), CDK9 (ENSG00000136807), CDK15 (ENSG00000138395), CDKL2 (ENSG00000138769), CDK19 (ENSG00000155111), CDK20 (ENSG00000156345), CDK5 (ENSG00000164885), CDK12 (ENSG00000167258), CDK1 (ENSG00000170312), CDK10 (ENSG00000185324), CDKL4 (ENSG00000205111), CDK11B (ENSG00000248333), CDK3 (ENSG00000250506)

Protein

Protein identifiers

Cyclin-dependent kinase 13 — Q14004 (reviewed: Q14004)

Alternative names: CDC2-related protein kinase 5, Cell division cycle 2-like protein kinase 5, Cell division protein kinase 13, Cholinesterase-related cell division controller

All UniProt accessions (10): Q14004, A0A2R8Y4Z0, A0A2R8Y644, A0A2R8Y7W5, A0A2R8Y7Y0, A0A2R8YCQ1, A0A2R8YD28, A0A2R8YEB7, A0A2R8YF61, A0A2R8YFE7

UniProt curated annotations — full annotation on UniProt →

Function. Cyclin-dependent kinase which displays CTD kinase activity and is required for RNA splicing. Has CTD kinase activity by hyperphosphorylating the C-terminal heptapeptide repeat domain (CTD) of the largest RNA polymerase II subunit RPB1, thereby acting as a key regulator of transcription elongation. Required for RNA splicing, probably by phosphorylating SRSF1/SF2. Required during hematopoiesis. In case of infection by HIV-1 virus, interacts with HIV-1 Tat protein acetylated at ‘Lys-50’ and ‘Lys-51’, thereby increasing HIV-1 mRNA splicing and promoting the production of the doubly spliced HIV-1 protein Nef.

Subunit / interactions. (Microbial infection) Interacts with human herpes virus 1 (HHV-1) transcriptional regulator ICP22. Interacts with CCNL1 and CCNL2. Interacts with CCNK. Interacts with C1QBP. (Microbial infection) Interacts with HIV-1 Tat.

Subcellular location. Nucleus speckle.

Tissue specificity. Expressed in fetal brain, liver, muscle and in adult brain. Also expressed in neuroblastoma and glioblastoma tumors.

Disease relevance. Congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (CHDFIDD) [MIM:617360] An autosomal dominant syndrome characterized by atrial and/or ventricular septal congenital heart defects, facial dysmorphism with hypertelorism, upslanted palpebral fissures, epicanthal folds, ptosis, strabismus, posteriorly rotated ears, thin upper lip, and small mouth. Patients manifest global developmental delay, delayed walking and speech acquisition, and intellectual disability. Some patients have mild microcephaly, a small cerebral cortex, and agenesis of corpus callosum. More variable features include clinodactyly and/or camptodactyly of the fingers, hypotonia, and joint hypermobility. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the protein kinase superfamily. CMGC Ser/Thr protein kinase family. CDC2/CDKX subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q14004-1	1	yes
Q14004-2	2

RefSeq proteins (2): NP_003709, NP_112557 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000719	Prot_kinase_dom	Domain
IPR008271	Ser/Thr_kinase_AS	Active_site
IPR011009	Kinase-like_dom_sf	Homologous_superfamily
IPR017441	Protein_kinase_ATP_BS	Binding_site
IPR050108	CDK	Family

Pfam: PF00069

Enzyme classification (BRENDA):

• EC 2.7.11.22 — cyclin-dependent kinase (BRENDA: 49 organisms, 441 substrates, 555 inhibitors, 8 Km, 4 kcat entries)
• EC 2.7.11.23 — [RNA-polymerase]-subunit kinase (BRENDA: 12 organisms, 155 substrates, 47 inhibitors, 15 Km, 0 kcat entries)

Substrate kinetics (BRENDA)

11 substrates with measured Km, best-characterized 11. Km ranges are aggregated across organisms/conditions.

Substrate	Km (mM)	Measurements
ATP	0.01–0.06	6
ADAQHATPPKKKRKVEDPKDF	0.046–0.521	2
ATP	0.0052–0.017	2
HEPTA-SIX PEPTIDE	0.189–0.2	2
L-ARG-HEPTA PEPTIDE	0.212–0.243	2
FIN1	0.003	1
PKTPKKAKKL	0.0029	1
CTD-CONTAINING FUSION PROTEIN	0.0002	1
GTP	0.18	1
SYNTHETIC PEPTIDE	0.15	1
[DNA-DIRECTED RNA POLYMERASE]	0.0001	1

Catalyzed reactions (Rhea), 3 shown:

• [DNA-directed RNA polymerase] + ATP = phospho-[DNA-directed RNA polymerase] + ADP + H(+) (RHEA:10216)
• L-seryl-[protein] + ATP = O-phospho-L-seryl-[protein] + ADP + H(+) (RHEA:17989)
• L-threonyl-[protein] + ATP = O-phospho-L-threonyl-[protein] + ADP + H(+) (RHEA:46608)

UniProt features (118 total): compositionally biased region 21, modified residue 20, sequence variant 18, helix 17, region of interest 11, strand 11, turn 6, sequence conflict 6, binding site 2, cross-link 2, chain 1, domain 1, active site 1, splice variant 1

Structure

Experimental structures (PDB)

2 structures.

PDB	Method	Resolution (Å)
5EFQ	X-RAY DIFFRACTION	2
7NXJ	X-RAY DIFFRACTION	2.36

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q14004-F1	50.59	0.19

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 837 (proton acceptor)

Ligand- & substrate-binding residues (2): 711–719; 734

Post-translational modifications (22): 315, 317, 325, 340, 342, 358, 360, 383, 395, 397, 400, 437, 439, 525, 556, 588, 871, 1048, 1058, 1246 …

Function

Pathways and Gene Ontology

Reactome pathways

8 pathways

ID	Pathway
R-HSA-6796648	TP53 Regulates Transcription of DNA Repair Genes
R-HSA-6798695	Neutrophil degranulation
R-HSA-168249	Innate Immune System
R-HSA-168256	Immune System
R-HSA-212436	Generic Transcription Pathway
R-HSA-3700989	Transcriptional Regulation by TP53
R-HSA-73857	RNA Polymerase II Transcription
R-HSA-74160	Gene expression (Transcription)

MSigDB gene sets: 410 (showing top): REACTOME_INNATE_IMMUNE_SYSTEM, SCHWAB_TARGETS_OF_BMYB_POLYMORPHIC_VARIANTS_DN, GOCC_SECRETORY_GRANULE, GOBP_NEGATIVE_REGULATION_OF_STEM_CELL_DIFFERENTIATION, GOBP_ALTERNATIVE_MRNA_SPLICING_VIA_SPLICEOSOME, MORF_ATRX, THEILGAARD_NEUTROPHIL_AT_SKIN_WOUND_DN, TGACCTY_ERR1_Q2, MORF_ESR1, CTATGCA_MIR153, RODRIGUES_NTN1_TARGETS_DN, MODULE_239, MORF_PPP5C, BLALOCK_ALZHEIMERS_DISEASE_UP, MORF_FANCG

GO Biological Process (22): alternative mRNA splicing, via spliceosome (GO:0000380), regulation of signal transduction (GO:0009966), hemopoiesis (GO:0030097), positive regulation of transcription elongation by RNA polymerase II (GO:0032968), positive regulation of transcription by RNA polymerase II (GO:0045944), negative regulation of stem cell differentiation (GO:2000737), mRNA processing (GO:0006397), protein phosphorylation (GO:0006468), epidermal growth factor receptor signaling pathway (GO:0007173), RNA splicing (GO:0008380), positive regulation of macrophage chemotaxis (GO:0010759), positive regulation of telomere maintenance (GO:0032206), regulation of stress-activated MAPK cascade (GO:0032872), cellular response to amino acid starvation (GO:0034198), stress-activated MAPK cascade (GO:0051403), regulation of cytoskeleton organization (GO:0051493), regulation of cell cycle (GO:0051726), response to epidermal growth factor (GO:0070849), caveolin-mediated endocytosis (GO:0072584), regulation of Golgi inheritance (GO:0090170), positive regulation of macrophage proliferation (GO:0120041), regulation of early endosome to late endosome transport (GO:2000641)

GO Molecular Function (15): RNA binding (GO:0003723), protein kinase activity (GO:0004672), cyclin-dependent protein serine/threonine kinase activity (GO:0004693), ATP binding (GO:0005524), RNA polymerase II CTD heptapeptide repeat kinase activity (GO:0008353), protein kinase binding (GO:0019901), cyclin binding (GO:0030332), protein serine kinase activity (GO:0106310), nucleotide binding (GO:0000166), protein serine/threonine kinase activity (GO:0004674), MAP kinase activity (GO:0004707), protein binding (GO:0005515), kinase activity (GO:0016301), transferase activity (GO:0016740), phosphatase binding (GO:0019902)

GO Cellular Component (16): cyclin K-CDK13 complex (GO:0002945), extracellular region (GO:0005576), obsolete extracellular space (GO:0005615), nucleus (GO:0005634), nucleoplasm (GO:0005654), Golgi apparatus (GO:0005794), cytosol (GO:0005829), cyclin/CDK positive transcription elongation factor complex (GO:0008024), nuclear speck (GO:0016607), nuclear cyclin-dependent protein kinase holoenzyme complex (GO:0019908), ficolin-1-rich granule lumen (GO:1904813), cyclin-dependent protein kinase holoenzyme complex (GO:0000307), early endosome (GO:0005769), late endosome (GO:0005770), caveola (GO:0005901), focal adhesion (GO:0005925)

Reactome top-level categories

Rollup of top-6 pathways:

Category	Pathways
Transcriptional Regulation by TP53	1
Innate Immune System	1
Immune System	1
RNA Polymerase II Transcription	1
Generic Transcription Pathway	1
Gene expression (Transcription)	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
protein serine/threonine kinase activity	3
cellular anatomical structure	3
RNA processing	2
MAPK cascade	2
protein kinase activity	2
cyclin-dependent protein kinase holoenzyme complex	2
intracellular membrane-bounded organelle	2
cytoplasm	2
endosome	2
mRNA splicing, via spliceosome	1
signal transduction	1
regulation of cell communication	1
regulation of signaling	1
regulation of response to stimulus	1
cell development	1
transcription elongation by RNA polymerase II	1
positive regulation of DNA-templated transcription, elongation	1
regulation of transcription elongation by RNA polymerase II	1
positive regulation of transcription by RNA polymerase II	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
positive regulation of DNA-templated transcription	1
negative regulation of cell differentiation	1
stem cell differentiation	1
regulation of stem cell differentiation	1
mRNA metabolic process	1
phosphorylation	1
protein modification process	1
ERBB signaling pathway	1
positive regulation of leukocyte chemotaxis	1
regulation of macrophage chemotaxis	1
macrophage chemotaxis	1
regulation of granulocyte chemotaxis	1
positive regulation of macrophage migration	1
telomere maintenance	1
regulation of telomere maintenance	1
positive regulation of DNA metabolic process	1
positive regulation of chromosome organization	1
regulation of MAPK cascade	1
stress-activated MAPK cascade	1

Protein interactions and networks

STRING

2304 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
CDK13	CCNK	O75909	997
CDK13	MMP23B	O75900	930
CDK13	MMP21	Q8N119	848
CDK13	CCNT1	O60563	763
CDK13	CCNT2	O60583	730
CDK13	CCNL2	Q96S94	670
CDK13	CCNH	P51946	667
CDK13	SUPT5H	O00267	614
CDK13	CCNC	P24863	602
CDK13	POLR2A	P24928	591
CDK13	CCNL1	Q9UK58	583
CDK13	CDK11B	P21127	560
CDK13	CTDP1	Q9Y5B0	557
CDK13	JAG2	Q9Y219	545
CDK13	CDK8	P49336	519

IntAct

86 interactions, top by confidence:

A	B	Type	Score
CDK4	CCND3	psi-mi:“MI:0914”(association)	0.980
CDK4	CDKN2A	psi-mi:“MI:0914”(association)	0.960
CDK2	CCNE2	psi-mi:“MI:0914”(association)	0.940
CCNK	CDK13	psi-mi:“MI:0407”(direct interaction)	0.830
CDK13	CCNK	psi-mi:“MI:0914”(association)	0.830
CDC37	CDK13	psi-mi:“MI:0915”(physical association)	0.560
RPS3	ZNF316	psi-mi:“MI:0914”(association)	0.530
JPH4	ZSWIM8	psi-mi:“MI:0914”(association)	0.530
MAGEB2	POLRMT	psi-mi:“MI:0914”(association)	0.530
SRPK2	RRP9	psi-mi:“MI:0914”(association)	0.530
SRSF5	CBX6	psi-mi:“MI:0914”(association)	0.530
CCNK	POLR2A	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
	CCNK	psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CCNK		psi-mi:“MI:0217”(phosphorylation reaction)	0.440
CDK13	H3-4	psi-mi:“MI:0915”(physical association)	0.400
CDK13	CHMP4A	psi-mi:“MI:0915”(physical association)	0.370
CDK13	CHMP5	psi-mi:“MI:0915”(physical association)	0.370
CDK13	CHMP6	psi-mi:“MI:0915”(physical association)	0.370
PRPF40A	CDK13	psi-mi:“MI:0915”(physical association)	0.370
CDK13	EEF2	psi-mi:“MI:0914”(association)	0.350
Lck	TLE5	psi-mi:“MI:0914”(association)	0.350
CDK1	CHEK1	psi-mi:“MI:0914”(association)	0.350
CDK2	MRPL27	psi-mi:“MI:0914”(association)	0.350
	AURKA	psi-mi:“MI:0914”(association)	0.350

BioGRID (231): CDK13 (Affinity Capture-MS), CCT3 (Affinity Capture-MS), EEF2 (Affinity Capture-MS), TUBB (Affinity Capture-MS), TUBB4B (Affinity Capture-MS), TUBB3 (Affinity Capture-MS), TUBB8 (Affinity Capture-MS), HSP90AA1 (Affinity Capture-MS), HSP90AB1 (Affinity Capture-MS), HSP90AB4P (Affinity Capture-MS), HSP90AB3P (Affinity Capture-MS), HSP90AA5P (Affinity Capture-MS), HSP90AA4P (Affinity Capture-MS), FKBP5 (Affinity Capture-MS), KEAP1 (Affinity Capture-MS)

ESM2 similar proteins: A1YFA7, A2T806, B0BN49, E1BB52, E9Q5K9, F1Q8W0, F4I2J8, F4JCU0, O60828, O74418, P0C196, P0CO16, P0CO17, P30651, P97868, Q10B98, Q14004, Q2HJC9, Q3KPW4, Q4IL82, Q4KLN7, Q4P4G8, Q4PB36, Q4PGL2, Q4V8I5, Q502P0, Q5AQ12, Q5F4A9, Q5RAA7, Q5U317, Q5XJD3, Q62504, Q66PJ3, Q6AXY7, Q6C1V6, Q6CEK8, Q6PCT5, Q6UN15, Q7Z6E9, Q80SY5

Diamond homologs: A2X6X1, A2XUW1, A8XA58, B5DE93, D2H526, E1BB50, E1BB52, O55076, O60145, O74456, O96821, P00546, P06493, P11440, P13863, P21127, P23111, P23437, P23572, P23573, P24033, P24100, P24788, P24923, P24941, P29618, P29619, P34112, P34117, P34556, P35567, P38973, P39951, P43063, P43450, P46551, P46892, P48734, P48963, P51958

SIGNOR signaling

30 interactions.

A	Effect	B	Mechanism
CDK13	“form complex”	CyclinK/CDK13	binding
CDK13	“up-regulates activity”	POLR2A	phosphorylation
CDK13	“up-regulates activity”	EIF4EBP1	phosphorylation
CDK13	“up-regulates activity”	EIF4B	phosphorylation
CDK13	“down-regulates quantity by destabilization”	SERINC5	phosphorylation
CCNO	“up-regulates activity”	CDK13	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 106 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Transport of Mature Transcript to Cytoplasm	8	39.5×	2e-09
mRNA 3’-end processing	10	25.6×	7e-10
G1 Phase	5	25.6×	3e-05
RNA Polymerase II Transcription Termination	8	22.8×	8e-08
Transport of Mature mRNA derived from an Intron-Containing Transcript	10	19.8×	5e-09
SARS-CoV-1-host interactions	7	16.0×	8e-06
mRNA Splicing	11	15.7×	6e-09
Cyclin D associated events in G1	5	15.1×	3e-04

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of mRNA splicing, via spliceosome	6	45.1×	2e-06
regulation of alternative mRNA splicing, via spliceosome	8	19.2×	3e-06
cytoplasmic translation	8	14.5×	1e-05
negative regulation of translation	7	13.4×	8e-05
ribosomal small subunit biogenesis	6	13.4×	3e-04
rRNA processing	9	12.5×	7e-06
RNA processing	5	10.7×	3e-03
G1/S transition of mitotic cell cycle	5	9.8×	4e-03

Disease & clinical

Clinical variants and AI predictions

ClinVar

1196 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	40
Likely pathogenic	37
Uncertain significance	576
Likely benign	345
Benign	79

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1164023	NM_003718.5(CDK13):c.2201A>C (p.Lys734Thr)	Pathogenic
1215514	NM_003718.5(CDK13):c.454C>T (p.Gln152Ter)	Pathogenic
1459507	NC_000007.13:g.(?39726267)(42262852_?)del	Pathogenic
1527352	GRCh37/hg19 7p14.1(chr7:40116335-40240160)	Pathogenic
1695188	NM_003718.5(CDK13):c.2227G>T (p.Glu743Ter)	Pathogenic
2034771	NM_003718.5(CDK13):c.352_353insCGGGCGGA (p.Arg118fs)	Pathogenic
2116449	NM_003718.5(CDK13):c.257dup (p.Leu87fs)	Pathogenic
2314381	NM_003718.5(CDK13):c.1228C>T (p.Arg410Ter)	Pathogenic
2413040	NM_003718.5(CDK13):c.1730C>A (p.Ser577Ter)	Pathogenic
2474613	NM_003718.5(CDK13):c.1959del (p.Glu654fs)	Pathogenic
2506768	NM_003718.5(CDK13):c.2141G>T (p.Gly714Val)	Pathogenic
2520825	NM_003718.5(CDK13):c.901del (p.Arg301fs)	Pathogenic
2744414	NM_003718.5(CDK13):c.950del (p.Ser317fs)	Pathogenic
2870817	NM_003718.5(CDK13):c.2782C>T (p.Arg928Ter)	Pathogenic
2871917	NM_003718.5(CDK13):c.3370C>T (p.Gln1124Ter)	Pathogenic
3063884	NM_003718.5(CDK13):c.930C>G (p.Tyr310Ter)	Pathogenic
3066156	NM_003718.5(CDK13):c.1783G>T (p.Glu595Ter)	Pathogenic
3233454	NM_003718.5(CDK13):c.1987A>T (p.Lys663Ter)	Pathogenic
3393580	NM_003718.5(CDK13):c.527del (p.Gly176fs)	Pathogenic
3661760	NM_003718.5(CDK13):c.2511T>A (p.Asp837Glu)	Pathogenic
3721620	NM_003718.5(CDK13):c.2854_2858del (p.Pro952fs)	Pathogenic
375737	NM_003718.5(CDK13):c.2149G>A (p.Gly717Arg)	Pathogenic
375738	NM_003718.5(CDK13):c.2140G>C (p.Gly714Arg)	Pathogenic
3764649	NM_003718.5(CDK13):c.2029A>T (p.Lys677Ter)	Pathogenic
3830808	NM_003718.5(CDK13):c.1197C>G (p.Tyr399Ter)	Pathogenic
3999572	NM_003718.5(CDK13):c.1688_1689dup (p.Val564Ter)	Pathogenic
422362	NM_003718.5(CDK13):c.2200A>G (p.Lys734Glu)	Pathogenic
4224485	NM_003718.5(CDK13):c.1128_1153dup (p.Ser385fs)	Pathogenic
423480	NM_003718.5(CDK13):c.2209C>T (p.Arg737Cys)	Pathogenic
449224	NM_003718.5(CDK13):c.2141G>A (p.Gly714Asp)	Pathogenic

SpliceAI

2824 predictions. Top by Δscore:

Variant	Effect	Δscore
7:39987597:A:AG	acceptor_gain	1.0000
7:39987597:AGAC:A	acceptor_gain	1.0000
7:39987598:G:GA	acceptor_gain	1.0000
7:39987598:GAC:G	acceptor_gain	1.0000
7:39987598:GACG:G	acceptor_gain	1.0000
7:39997621:G:GT	donor_gain	1.0000
7:39997622:A:T	donor_gain	1.0000
7:39997642:T:G	donor_gain	1.0000
7:39997656:G:GT	donor_gain	1.0000
7:39997658:GGCC:G	donor_gain	1.0000
7:39997659:GCC:G	donor_gain	1.0000
7:39997661:C:G	donor_gain	1.0000
7:39997665:G:GG	donor_gain	1.0000
7:40001856:A:AG	acceptor_gain	1.0000
7:40001856:AATAG:A	acceptor_gain	1.0000
7:40001857:A:G	acceptor_gain	1.0000
7:40001859:A:AG	acceptor_gain	1.0000
7:40001859:A:C	acceptor_loss	1.0000
7:40001859:AG:A	acceptor_gain	1.0000
7:40001860:G:GG	acceptor_gain	1.0000
7:40001860:GG:G	acceptor_gain	1.0000
7:40001860:GGA:G	acceptor_gain	1.0000
7:40001860:GGAGA:G	acceptor_gain	1.0000
7:40002027:CAAAG:C	donor_gain	1.0000
7:40002028:AAAGG:A	donor_loss	1.0000
7:40002029:AAG:A	donor_gain	1.0000
7:40002030:AG:A	donor_gain	1.0000
7:40002031:GG:G	donor_gain	1.0000
7:40002032:G:GG	donor_gain	1.0000
7:40002033:T:A	donor_loss	1.0000

AlphaMissense

9791 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
7:39987729:A:C	S448R	1.000
7:39987731:C:A	S448R	1.000
7:39987731:C:G	S448R	1.000
7:39987745:T:C	L453S	1.000
7:39999407:T:A	W697R	1.000
7:39999407:T:C	W697R	1.000
7:39999431:T:A	F705I	1.000
7:39999431:T:C	F705L	1.000
7:39999431:T:G	F705V	1.000
7:39999432:T:C	F705S	1.000
7:39999432:T:G	F705C	1.000
7:39999433:T:A	F705L	1.000
7:39999433:T:G	F705L	1.000
7:39999452:G:A	G712R	1.000
7:39999452:G:C	G712R	1.000
7:39999453:G:A	G712E	1.000
7:39999453:G:T	G712V	1.000
7:39999456:A:T	E713V	1.000
7:39999458:G:A	G714S	1.000
7:39999458:G:C	G714R	1.000
7:39999458:G:T	G714C	1.000
7:39999459:G:A	G714D	1.000
7:39999459:G:C	G714A	1.000
7:39999459:G:T	G714V	1.000
7:39999462:C:T	T715I	1.000
7:39999464:T:A	Y716N	1.000
7:39999464:T:C	Y716H	1.000
7:39999464:T:G	Y716D	1.000
7:39999465:A:G	Y716C	1.000
7:39999467:G:A	G717R	1.000

dbSNP variants (sampled 300 via entrez): RS1000004443 (7:40054517 G>C), RS1000039978 (7:40068466 C>T), RS1000056906 (7:39971738 C>G), RS1000064506 (7:40049857 A>G), RS1000091840 (7:40007887 G>A), RS1000096118 (7:40054107 T>C), RS1000130652 (7:39975672 C>T), RS1000134246 (7:40090931 C>A), RS1000136887 (7:40028772 C>T), RS1000152903 (7:39967482 A>T), RS1000163252 (7:40009211 T>G), RS1000173728 (7:40085483 A>G), RS1000182538 (7:39972582 C>T), RS1000207694 (7:40006723 A>C), RS1000213239 (7:39958553 C>T)

Disease associations

OMIM: gene MIM:603309 | disease phenotypes: MIM:617360, MIM:146510, MIM:175700

GenCC curated gene-disease

Disease	Classification	Inheritance
congenital heart defects, dysmorphic facial features, and intellectual developmental disorder	Definitive	Autosomal dominant

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
syndromic intellectual disability	Definitive	AD

Mondo (9): congenital heart defects, dysmorphic facial features, and intellectual developmental disorder (MONDO:0044302), Pallister-Hall syndrome (MONDO:0007804), Greig cephalopolysyndactyly syndrome (MONDO:0008287), syndromic intellectual disability (MONDO:0000508), neurodevelopmental disorder (MONDO:0700092), autism spectrum disorder (MONDO:0005258), intellectual disability (MONDO:0001071), cardiomyopathy (MONDO:0004994), primary amenorrhea (MONDO:1060208)

Orphanet (7): CDK13-related developmental delay-intellectual disability-facial dysmorphism-congenital heart defects syndrome (Orphanet:646278), Greig cephalopolysyndactyly syndrome (Orphanet:380), Pallister-Hall syndrome (Orphanet:672), Rare genetic syndromic intellectual disability (Orphanet:183763), Rare cardiomyopathy (Orphanet:167848), NON RARE IN EUROPE: Autism (Orphanet:106), NON RARE IN EUROPE: Unexplained intellectual disability (Orphanet:319658)

HPO phenotypes

67 total (30 of 67 shown, HPO-id order):

HPO	Term
HP:0000006	Autosomal dominant inheritance
HP:0000160	Narrow mouth
HP:0000200	Short lingual frenulum
HP:0000215	Thick upper lip vermilion
HP:0000219	Thin upper lip vermilion
HP:0000233	Thin vermilion border
HP:0000252	Microcephaly
HP:0000269	Prominent occiput
HP:0000286	Epicanthus
HP:0000316	Hypertelorism
HP:0000319	Smooth philtrum
HP:0000322	Short philtrum
HP:0000324	Facial asymmetry
HP:0000356	Abnormality of the outer ear
HP:0000358	Posteriorly rotated ears
HP:0000369	Low-set ears
HP:0000396	Overfolded helix
HP:0000414	Bulbous nose
HP:0000426	Prominent nasal bridge
HP:0000431	Wide nasal bridge
HP:0000486	Strabismus
HP:0000506	Telecanthus
HP:0000508	Ptosis
HP:0000574	Thick eyebrow
HP:0000581	Blepharophimosis
HP:0000582	Upslanted palpebral fissure
HP:0000691	Microdontia
HP:0000717	Autism
HP:0000750	Delayed speech and language development
HP:0001249	Intellectual disability

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST004751_14	Serum uric acid levels in response to allopurinol in gout	3.000000e-06
GCST90002388_387	Lymphocyte count	2.000000e-18
GCST90002389_153	Lymphocyte percentage of white cells	1.000000e-09
GCST90002399_174	Neutrophil percentage of white cells	3.000000e-09
GCST90002400_610	Plateletcrit	3.000000e-10

EFO canonical traits (5, from GWAS)

EFO ID	Trait name
EFO:0004761	uric acid measurement
EFO:0004587	lymphocyte count
EFO:0007993	lymphocyte percentage of leukocytes
EFO:0007990	neutrophil percentage of leukocytes
EFO:0007985	platelet crit

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D009202	Cardiomyopathies	C14.280.238
D008607	Intellectual Disability	C10.597.606.360; C23.888.592.604.646; F01.700.687; F03.625.539
D065886	Neurodevelopmental Disorders	F03.625
D054975	Pallister-Hall Syndrome	C04.445.622; C04.588.614.250.195.885.500.299; C05.660.585.600.374; C10.228.140.211.885.500.299; C10.228.140.617.477.299; C10.551.240.250.700.500.249; C16.131.077.690; C16.131.621.585.600.374
C537300	Greig cephalopolysyndactyly syndrome (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (5): CHEMBL1795192 (SINGLE PROTEIN), CHEMBL3559691 (PROTEIN FAMILY), CHEMBL4296067 (PROTEIN COMPLEX), CHEMBL4630753 (PROTEIN FAMILY), CHEMBL5169085 (PROTEIN-PROTEIN INTERACTION)

Molecules with ChEMBL bioactivity

20 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 60,896 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL2103840	DINACICLIB	3	2,257
CHEMBL223360	LINIFANIB	3	3,925
CHEMBL3137331	DEFACTINIB	3	1,229
CHEMBL38380	FASUDIL	3	11,953
CHEMBL428690	ALVOCIDIB	3	27,781
CHEMBL603469	LESTAURTINIB	3
CHEMBL103667	DORAMAPIMOD	2	1,681
CHEMBL1230609	FORETINIB	2	3,096
CHEMBL215152	DEFOSBARASERTIB	2	372
CHEMBL3544964	RAVOXERTINIB	2	1,243
CHEMBL384304	RG-547	2	93
CHEMBL445813	AT-7519	2	2,614
CHEMBL5199065	ISTISOCICLIB	2	21
CHEMBL1276127	INDIRUBIN	2	181
CHEMBL1084546	PF-00562271	1	399
CHEMBL1230607	PHA-793887	1	299
CHEMBL2140408	AMG-900	1	675
CHEMBL296468	BMS-387032	1	2,075
CHEMBL3545083	RGB-286638	1	551
CHEMBL574738	AST-487	1	451

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: enzyme — CRK7 subfamily

Most potent curated ligand interactions (2 total), top 2:

Ligand	Action	Affinity	Parameter
CDK12 inhibitor 2	Inhibition	8.0	pIC50
YJZ5118	Inhibition	7.58	pIC50

Binding affinities (BindingDB)

1 measured of 1 human assays (1 total across all organisms); most potent 1 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
N-(5-cyclopropyl-1H-pyrazol-3-yl)-2-(1’-propioloyl-1’,2’,3’,6’-tetrahydro-[2,4’- bipyridin]-5-yl)propanamide	IC50	7 nM	US-10894786: Substituted pyrazole derivatives as selective CDK12/13 inhibitors

ChEMBL bioactivities

264 potent at pChembl≥5 of 266 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
9.05	IC50	0.9	nM	CHEMBL4797074
9.03	Kd	0.94	nM	AST-487
8.70	Kd	2	nM	CHEMBL4855324
8.68	EC50	2.1	nM	CHEMBL5178057
8.52	IC50	3	nM	CHEMBL4778361
8.52	IC50	3	nM	CHEMBL4781207
8.52	IC50	3	nM	CHEMBL4784925
8.49	Kd	3.2	nM	AT-7519
8.42	IC50	3.8	nM	CHEMBL4760738
8.41	IC50	3.9	nM	CHEMBL4744778
8.40	IC50	4	nM	CHEMBL4759298
8.40	IC50	4	nM	CHEMBL4791883
8.40	Kd	4	nM	CHEMBL4847754
8.40	IC50	4	nM	CHEMBL4847754
8.37	IC50	4.3	nM	CHEMBL4788447
8.35	EC50	4.5	nM	CHEMBL5205494
8.31	Kd	4.9	nM	CHEMBL4877117
8.30	IC50	5	nM	CHEMBL4740577
8.30	IC50	5	nM	CHEMBL4777358
8.30	IC50	5	nM	CHEMBL4786926
8.30	Kd	5	nM	CHEMBL4852083
8.30	Kd	5	nM	CHEMBL4877117
8.30	IC50	5	nM	CHEMBL4852083
8.30	IC50	5	nM	CHEMBL4877117
8.24	IC50	5.8	nM	CHEMBL4792293
8.22	IC50	6	nM	CHEMBL4778361
8.22	IC50	6	nM	CHEMBL4781207
8.22	IC50	6	nM	CHEMBL4778676
8.22	IC50	6	nM	CHEMBL4776295
8.22	Kd	6	nM	CHEMBL4868958
8.21	EC50	6.2	nM	CHEMBL5193459
8.16	IC50	6.9	nM	CHEMBL4778676
8.15	IC50	7	nM	CHEMBL4800122
8.15	IC50	7	nM	CHEMBL4784656
8.15	EC50	7.1	nM	CHEMBL5186403
8.15	IC50	7	nM	CHEMBL5917807
8.07	Kd	8.6	nM	CHEMBL4160662
8.07	EC50	8.5	nM	CHEMBL5182667
8.05	Kd	9	nM	CHEMBL4867928
8.04	IC50	9.22	nM	CHEMBL5929886
8.00	IC50	10	nM	CHEMBL4160662
8.00	IC50	10	nM	CHEMBL4799777
8.00	IC50	10	nM	CHEMBL4211454
8.00	IC50	10	nM	CHEMBL5193291
7.93	IC50	11.7	nM	CHEMBL4781668
7.92	IC50	12	nM	CHEMBL4778214
7.92	IC50	12	nM	CHEMBL5169449
7.92	IC50	12	nM	CHEMBL5998973
7.91	IC50	12.2	nM	CHEMBL6147235
7.90	EC50	12.5	nM	CHEMBL5200971

PubChem BioAssay actives

94 with measured affinity, of 644 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-[4-[(4-ethylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl]-3-[4-[6-(methylamino)pyrimidin-4-yl]oxyphenyl]urea	624761: Binding constant for CDC2L5 kinase domain	kd	0.0009	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0021	uM
4-[(2,6-dichlorobenzoyl)amino]-N-piperidin-4-yl-1H-pyrazole-5-carboxamide	624761: Binding constant for CDC2L5 kinase domain	kd	0.0032	uM
4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]piperazine-1-carboxamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0045	uM
N-[(5,6-dichloro-1H-benzimidazol-2-yl)methyl]-9-(1-methylpyrazol-4-yl)-2-morpholin-4-ylpurin-6-amine	1890148: Binding affinity to CDK13 (unknown origin) assessed as dissociation constant	kd	0.0049	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-3-oxo-1H-isoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0062	uM
2-[4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]piperazin-1-yl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]acetamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0071	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[[2-(2,6-dioxopiperidin-3-yl)-1-oxo-3H-isoindol-5-yl]amino]acetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0085	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-(1-methyl-6-oxo-3-pyridinyl)phenyl]urea	1870804: Binding affinity to human CDK13 (694 to 1039 residues)/CyclinK (1 to 267 residues) expressed in baculovirus infected in Sf9 cells by Biolayer interferometry	kd	0.0086	uM
5-(2-aminoethylsulfanyl)-3-cyclobutyl-N-[(4-pyridin-2-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0120	uM
3-[4-[4-[benzylcarbamoyl-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]amino]phenyl]piperazin-1-yl]-N-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]propanamide	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0125	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-(4-piperazin-1-ylphenyl)urea	1870804: Binding affinity to human CDK13 (694 to 1039 residues)/CyclinK (1 to 267 residues) expressed in baculovirus infected in Sf9 cells by Biolayer interferometry	kd	0.0170	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[(E)-3-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]prop-2-enoyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0207	uM
2-[(2S)-1-[3-ethyl-7-[(1-oxidopyridin-1-ium-3-yl)methylamino]pyrazolo[1,5-a]pyrimidin-5-yl]piperidin-2-yl]ethanol	1424940: Kinobeads (epsilon), multiple immobilized ATP-competitive broad spectrum kinase inhibitors, used to assess residual binding of ~300 proteins simultaneously from cell lysate in the presence of a compound. Quantitative readout performed by mass spectrometry.	kd	0.0210	uM
4-N-[4-[5-(cyclopropylmethyl)-1-methylpyrazol-4-yl]-5-fluoropyrimidin-2-yl]cyclohexane-1,4-diamine	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0215	uM
5-(2-aminoethylsulfanyl)-3-cyclobutyl-N-[(4-pyrazol-1-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0220	uM
5-(2-aminoethylsulfanyl)-3-propan-2-yl-N-[(4-pyrazin-2-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0220	uM
N-[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]piperidine-4-carboxamide	624761: Binding constant for CDC2L5 kinase domain	kd	0.0230	uM
N-[3-[[3-ethyl-5-[(2S)-2-(2-hydroxyethyl)piperidin-1-yl]pyrazolo[1,5-a]pyrimidin-7-yl]amino]phenyl]prop-2-enamide	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0293	uM
3-benzyl-1-[4-[(5-cyano-2-pyridinyl)amino]cyclohexyl]-1-[4-[4-[2-[2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindol-5-yl]oxyacetyl]piperazin-1-yl]phenyl]urea	1870807: Protac activity at CRBN/CDK13 in human MDA-MB-231 cells assessed as induction of CDK13 degradation incubated for 15 hrs by immunoblotting analysis	ec50	0.0360	uM
1-[4-(3-amino-1H-indazol-4-yl)phenyl]-3-(2-fluoro-5-methylphenyl)urea	624761: Binding constant for CDC2L5 kinase domain	kd	0.0380	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.0400	uM
N-[4-[(3R)-3-[[5-[(5-tert-butyl-1,3-oxazol-2-yl)methylsulfanyl]-1,3-thiazol-2-yl]amino]piperidine-1-carbonyl]phenyl]prop-2-enamide	1652531: Inhibition of human CDK13/cyclin K using Pol2-CTD as substrate by [gamma-33P]ATP-based radioisotope filter binding assay	ic50	0.0490	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]pyrrolidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.0502	uM
(2S,3R,4R,6R)-3-methoxy-2-methyl-4-(methylamino)-29-oxa-1,7,17-triazaoctacyclo[12.12.2.12,6.07,28.08,13.015,19.020,27.021,26]nonacosa-8,10,12,14,19,21,23,25,27-nonaen-16-one	1356600: Inhibition of N-terminal FLAG-tagged human full-length CDK13 (1 to 1512 residues)/N-terminal His-tagged CycK (1 to 580 residues) expressed in Sf9 cells assessed as reduction in ATP-dependent ULight-4E-BP1 (Thr37/Thr46) substrate peptide phosphorylation pre-incubated for 60 mins by LANCE Ultra assay	ic50	0.0570	uM
5-(2-aminoethylsulfanyl)-N-[(4-imidazol-1-ylphenyl)methyl]-3-propan-2-yl-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.0670	uM
(E)-N-[4-[(3S)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1653046: Inhibition of CDK13 (unknown origin)	ic50	0.0690	uM
[4-amino-2-[(1-methylsulfonylpiperidin-4-yl)amino]pyrimidin-5-yl]-(2,3-difluoro-6-methoxyphenyl)methanone	624761: Binding constant for CDC2L5 kinase domain	kd	0.1100	uM
(E)-N-[6-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-pyridinyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1200	uM
1-[[3-propan-2-yl-7-[(4-pyrazol-1-ylphenyl)methylamino]-2H-pyrazolo[4,3-d]pyrimidin-5-yl]sulfanyl]propan-2-ol	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.1220	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]phenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1230	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-fluorophenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1266	uM
2-N-[4-(3-aminopropylamino)phenyl]-4-N-(5-cyclopropyl-1H-pyrazol-3-yl)pyrimidine-2,4-diamine	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.1545	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]phenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1776	uM
(E)-N-[4-[(1S,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]cyclohexyl]oxyphenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1820	uM
4-(4-methylpiperazin-1-yl)-N-[4-(2-methyl-3-propan-2-ylindazol-5-yl)pyrimidin-2-yl]quinolin-7-amine	1771111: Inhibition of human CDK13/cyclin-K incubated for 2 hrs by [gamma-33P]-ATP assay	ic50	0.1820	uM
(E)-N-[6-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-3-pyridinyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.1861	uM
N-[4-[(4-methylpiperazin-1-yl)methyl]phenyl]-4-(7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-1H-pyrazole-5-carboxamide	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.1872	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-5-fluoro-2-methylphenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.2038	uM
3-[3-[4-(1-methylindol-3-yl)-2,5-dioxopyrrol-3-yl]indol-1-yl]propyl carbamimidothioate	1983417: Inhibition of CDK13/Cyclin K (unknown origin) preincubated for 10 mins followed by substrate and ATP addition measured after 200 mins by ADP-Glo luminescence assay	ic50	0.2064	uM
1-N’-[3-fluoro-4-[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxyphenyl]-1-N-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide	624761: Binding constant for CDC2L5 kinase domain	kd	0.2100	uM
N-[3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]phenyl]-4-[[(E)-4-(dimethylamino)but-2-enoyl]amino]benzamide	1743748: Inhibition of CDK13 (unknown origin)	ic50	0.2250	uM
(E)-N-[4-[(3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidin-1-yl]-2-methylphenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.2388	uM
(E)-N-[4-[(1R,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]cyclohexyl]oxyphenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.2826	uM
(E)-N-[4-[(1R,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]cyclohexyl]oxyphenyl]but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.3281	uM
5-(2-aminoethylsulfanyl)-3-cyclopentyl-N-[(4-pyridin-2-ylphenyl)methyl]-2H-pyrazolo[4,3-d]pyrimidin-7-amine	1880980: Inhibition of GST-tagged human CDK13/Cyclin K expressed in Sf9 cells using RBER-IRStide peptide as substrate in presence of ATP and [gamma33-P] ATP by radioisotope filter binding assay	ic50	0.3340	uM
trans-(1S,3S)-3-N-(5-pentan-3-ylpyrazolo[1,5-a]pyrimidin-7-yl)cyclopentane-1,3-diamine	1921498: Inhibition of CDK13 (unknown origin) incubated for 120 mins in presence of ATP by HotSpot kinase assay	ic50	0.3720	uM
2-(2-chlorophenyl)-5,7-dihydroxy-8-[(3S,4R)-3-hydroxy-1-methylpiperidin-4-yl]chromen-4-one	624761: Binding constant for CDC2L5 kinase domain	kd	0.4300	uM
(E)-N-[4-[(1R,3R)-3-[[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]cyclohexyl]oxy-3-fluorophenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.4842	uM
(E)-N-[4-[(3R)-3-[[5-bromo-4-(1H-indol-3-yl)pyrimidin-2-yl]amino]piperidine-1-carbonyl]phenyl]-4-(dimethylamino)but-2-enamide	1769507: Inhibition of human recombinant CDK13/CyclinK assessed as reduction in substrate phosphorylation using His-c-Myc as substrate preincubated with enzyme for 5 mins followed by substrate addition for 15 mins in presence of [gamma 32P-ATP] by radioactive kinase assay	ic50	0.5726	uM

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cadmium	increases abundance, affects reaction, decreases expression	2
Formaldehyde	decreases expression, increases expression	2
Valproic Acid	decreases expression, increases methylation	2
7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide	decreases expression	2
FR900359	affects phosphorylation	1
ginger extract	decreases expression, increases abundance	1
geldanamycin	increases expression	1
bisphenol A	decreases expression	1
lead acetate	affects cotreatment, increases expression	1
cypermethrin	decreases expression	1
zinc protoporphyrin	affects cotreatment, increases expression	1
sodium arsenite	increases expression	1
coumarin	decreases phosphorylation	1
2-amino-3,8-dimethylimidazo(4,5-f)quinoxaline	increases expression	1
2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine	increases expression	1
polyhexamethyleneguanidine	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	decreases expression	1
Irinotecan	decreases expression	1
Leflunomide	decreases expression	1
Air Pollutants	increases abundance, affects expression	1
Caffeine	affects phosphorylation	1
Coumestrol	decreases expression	1
Doxorubicin	decreases expression	1
Emodin	decreases expression	1
Estradiol	affects expression	1
Hydrogen Peroxide	affects cotreatment, increases expression	1
Menthol	increases expression	1
Nicotine	increases expression	1
Oils, Volatile	decreases expression, increases abundance	1

ChEMBL screening assays

257 unique, capped per target: 250 binding, 7 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1174102	Binding	Inhibition of CDC2L5 at 10 uM	Broad spectrum alkynyl inhibitors of T315I Bcr-Abl. — Bioorg Med Chem Lett
CHEMBL5445783	Functional	Affinity Phenotypic Cellular interaction: (In-Cell western blot (using MDA-MB-231 cells)) EUB0001632a CDK13	Affinity Phenotypic Cellular Literature for EUbOPEN Chemogenomic Library

Cellosaurus cell lines

3 cell lines: 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_SI21	HAP1 CDK13 (-) 1	Cancer cell line	Male
CVCL_SI22	HAP1 CDK13 (-) 2	Cancer cell line	Male
CVCL_SI23	HAP1 CDK13 (-) 3	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT00391261	PHASE4	COMPLETED	An Open-label Trial of Metformin for Weight Control of Pediatric Patients on Antipsychotic Medications.
NCT01028820	PHASE4	COMPLETED	FMRI Brain Activation of Aripiprazole Treatment in Autism Spectrum Disorders
NCT01333865	PHASE4	COMPLETED	A Study of Memantine Hydrochloride (Namenda®) for Cognitive and Behavioral Impairment in Adults With Autism Spectrum Disorders
NCT01337700	PHASE4	COMPLETED	Milnacipran in Autism and the Functional Locus Coeruleus and Noradrenergic Model of Autism
NCT01695200	PHASE4	COMPLETED	Omega-3 Fatty Acids in Autism Spectrum Disorders
NCT02096952	PHASE4	COMPLETED	Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
NCT02235467	PHASE4	COMPLETED	Multisite Study: Parental Training Using Video Modelling to Develop Social Skills in Children With Autism
NCT02940574	PHASE4	COMPLETED	Neural and Behavioral Effects of Oxytocin in Autism Spectrum Disorders
NCT03333629	PHASE4	COMPLETED	Promoting Positive Outcomes for Individuals With ASD: Linking Early Detection, Treatment, and Long-term Outcomes
NCT03337646	PHASE4	COMPLETED	Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
NCT03538431	PHASE4	COMPLETED	Improving Driving in Young People With Autism Spectrum Disorders
NCT03757585	PHASE4	COMPLETED	Natural Treatments for the Management of Emotional Dysregulation in Youth With Non-verbal Learning Disability (NVLD) and/or Autism Spectrum Disorders (ASD)
NCT04903353	PHASE4	COMPLETED	Pragmatic Trial Comparing Weight Gain in Children With Autism Taking Risperidone Versus Aripiprazole
NCT05063656	PHASE4	COMPLETED	Biomarker-Driven Pharmacological Treatment of Adolescents With Autism Spectrum Disorder With Gabapentin
NCT05146245	PHASE4	UNKNOWN	Safety and Pharmacokinetics of Antipsychotics in Children 2: Studying TDM in an RCT
NCT05916339	PHASE4	RECRUITING	AWARE: Management of ADHD in Autism Spectrum Disorder
NCT05954052	PHASE4	TERMINATED	A Study of Glutathione in Children With Autism Spectrum Disorder
NCT06853665	PHASE4	RECRUITING	The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine
NCT07054697	PHASE4	COMPLETED	Pilot-RCT With Individualized Homeopathic Treatment in the Children With Autism Spectrum Disorder
NCT07161804	PHASE4	COMPLETED	Pilot RCT Using Homeopathic Medicines in ASD
NCT07439042	PHASE4	NOT_YET_RECRUITING	Buspirone for Anxiety in Autistic Youth
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT01302964	PHASE3	COMPLETED	Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
NCT01706523	PHASE3	TERMINATED	Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders
NCT01825798	PHASE3	COMPLETED	Treatment of Overweight Induced by Antipsychotic Medication in Young People With Autism Spectrum Disorders (ASD)
NCT01972074	PHASE3	COMPLETED	Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder
NCT02985749	PHASE3	COMPLETED	A Study of Oxytocin for the Treatment of Social Impairment in Individuals With High Functioning Autism Spectrum Disorder
NCT03197922	PHASE3	COMPLETED	Treatment of Encopresis in Children With Autism Spectrum Disorders
NCT03504917	PHASE3	TERMINATED	A Study of Balovaptan in Adults With Autism Spectrum Disorder With a 2-Year Open-Label Extension
NCT03553875	PHASE3	TERMINATED	Memantine for the Treatment of Social Deficits in Youth With Disorders of Impaired Social Interactions
NCT03640156	PHASE3	COMPLETED	Modulating Socially Adaptive Mirror System Functioning in Autism by Oxytocin
NCT03715153	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715166	PHASE3	TERMINATED	Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than 18 Years Old With Autism Spectrum Disorder
NCT04233502	PHASE3	WITHDRAWN	Efficacy and Safety of Slenyto for Insomnia in Children With ASD
NCT04578756	PHASE3	COMPLETED	Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum Disorder